Photo - Redwave Medical GmbH
54159

Redwave Medical GmbH

Germany
Market: Medicine
Stage of the project: Operating business

Date of last change: 07.10.2021
Show contacts
0
equalizer from 2000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Idea

The future beyond blood pressure measurement - Shaping the future of cardiovascular health towards predictive medicine with our medical-grade algorithms for cardiovascular diagnostics.

Current Status

3 years after company foundation we launched our first invasively validated medical algorithm in spring 2020, leading to first revenue with our first B2B customer by implementation into his product line for cardiology practices. Besides increasing sales of this product line, we are in negotiations or market entry preparations with over 5 other customers. To date, we are financed by 2M € Seed stage VC and Horizon Europe. We just opened our Series-A stage for targeting new international customers to set up the stage for future algorithms, mainly for cuffless and contactless medical applications.

Problem or Opportunity

In the last 150 years, our life span has doubled. Blood pressure measurement (BPM) contributed greatly to this and is still the most frequently performed medical examination worldwide. Nevertheless, the last 25 years of life are dominated by cardiovascular diseases.
BPM is inadequate to help minimizing those years and increase the health span instead, because it only detects a problem when it is already established, i.e. high blood pressure and underlying vessel damage are already pronounced. Now it is time to maximise the health span: the period during which we live free of chronic diseases.

Solution (product or service)

The solution is to determine the cardiovascular phenotype instead of blood pressure values, based on analysing the underlying biosignal: the pulse wave. Pulse wave analysis interprets the entire topography, shape and characteristics of the pulse waves. Thus, it detects underlying changes of heart, vessels or hemodynamic regulation long before the blood pressure rises and enables any form of individual preventive therapy.
Pulse wave phenotyping can be used anywhere blood pressure is measured today: as a single measurement e.g. in doctor's offices, clinics, and as trend monitoring at home.

Business model

Our business model is quantity-based B2B software licencing modules of our medical algorithms with fixed quarterly pre-payments. We also offer pay-per-use, which is interesting for future telemedicine integrations and e-health platforms. Additionally, affiliations for therapy provides are a future revenue potential.
In terms of technology commercialization: our Antares algorithm for cuff-based measurement of central blood pressure and pulse wave velocity is commercially available in the first devices of our customers. On the medical side, it is validated against the invasive gold standard.
5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility8
star0
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Idea
Current Status
Market
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Invested in previous rounds, $
Business model
Money will be spent on
Offer for investor
Team or Management
Mentors & Advisors
Lead investor
Risks
Incubation/Acceleration programs accomplishment
Won the competition and other awards
Invention/Patent
Photos
Product Video